» Articles » PMID: 27158908

Electrocardiographic Abnormalities and Treatment with Benznidazole Among Children with Chronic Infection by Trypanosoma Cruzi: A Retrospective Cohort Study

Overview
Date 2016 May 10
PMID 27158908
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chronic infection by Trypanosoma cruzi could cause heart conduction disturbances. We sought to analyze electrocardiographic abnormalities among children with chronic T. cruzi infection with and without trypanocidal treatment with benznidazole.

Methodology/principal Findings: We studied 111 children 6-16 years of age with asymptomatic chronic T. cruzi infection who were recruited in 1991-1992 in Salta, Argentina. Most children were randomly assigned to benznidazole 5 mg/Kg/day (n = 47) or matching placebo (n = 48) for 60 days. Remaining children (n = 16) received treatment with benznidazole 5 mg/Kg/day open-label. Electrocardiograms were obtained at baseline and in 1995-1996, 1998, 2000 and 2005, and were analyzed using the Buenos Aires method. Among the 94 children with an electrocardiogram at baseline, 8 (8.5%) had electrocardiographic abnormalities, including 4 (4.7%) children with right bundle branch block. Proportion of abnormal electrocardiograms in the full population (n = 111) remained constant over time (media follow-up 8.6 years). Multivariable adjusted prevalence ratios (95% confidence interval [95%CI]) for electrocardiographic abnormalities in 1995-1996, 1998, 2000 and 2005 comparing children treated with benznidazole versus those not treated were 2.76 (0.66, 11.60), 2.33 (0.44, 12.31), 3.06 (0.48, 19.56), and 1.94 (0.33, 11.25), respectively. Among the 86 children with a normal electrocardiogram at baseline, 16 (18.6%) developed electrocardiographic abnormalities during follow-up. The multivariable adjusted hazard ratio for incident electrocardiographic abnormalities comparing children treated with benznidazole versus those not treated was 0.68 (95%CI: 0.25, 1.88).

Conclusions/significance: Electrocardiographic abnormalities are frequent among children with chronic T. cruzi infection. Treatment with benznidazole for 60 days may not be associated with less electrocardiographic abnormalities.

Citing Articles

Impact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysis.

Rassi Jr A, Grimshaw A, Sarwal A, Sah R, Shah S, Higuita N EClinicalMedicine. 2025; 79():102972.

PMID: 39810938 PMC: 11732499. DOI: 10.1016/j.eclinm.2024.102972.


Long-term cardiology outcomes in children after early treatment for Chagas disease, an observational study.

Gonzalez N, Moscatelli G, Moroni S, Ballering G, Jurado L, Falk N PLoS Negl Trop Dis. 2022; 16(12):e0010968.

PMID: 36534647 PMC: 9810160. DOI: 10.1371/journal.pntd.0010968.


A Rapid Review on the Efficacy and Safety of Pharmacological Treatments for Chagas Disease.

Malone C, Nevis I, Fernandez E, Sanchez A Trop Med Infect Dis. 2021; 6(3).

PMID: 34287382 PMC: 8293415. DOI: 10.3390/tropicalmed6030128.


Risk of Chronic Cardiomyopathy Among Patients With the Acute Phase or Indeterminate Form of Chagas Disease: A Systematic Review and Meta-analysis.

Chadalawada S, Sillau S, Archuleta S, Mundo W, Bandali M, Parra-Henao G JAMA Netw Open. 2020; 3(8):e2015072.

PMID: 32865573 PMC: 7489816. DOI: 10.1001/jamanetworkopen.2020.15072.


Progression of Baseline Electrocardiogram Abnormalities in Chagas Patients Undergoing Antitrypanosomal Treatment.

Soverow J, Hernandez S, Sanchez D, Forsyth C, Flores C, Viana G Open Forum Infect Dis. 2019; 6(2):ofz012.

PMID: 30793005 PMC: 6377566. DOI: 10.1093/ofid/ofz012.


References
1.
Sosa-Estani S, Segura E . Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis. 2006; 19(6):583-7. DOI: 10.1097/01.qco.0000247592.21295.a5. View

2.
de Andrade A, Zicker F, de Oliveira R, Almeida Silva S, Luquetti A, Travassos L . Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996; 348(9039):1407-13. DOI: 10.1016/s0140-6736(96)04128-1. View

3.
Lee B, Bacon K, Bottazzi M, Hotez P . Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 2013; 13(4):342-8. PMC: 3763184. DOI: 10.1016/S1473-3099(13)70002-1. View

4.
Perez-Molina J, Perez-Ayala A, Moreno S, Fernandez-Gonzalez M, Zamora J, Lopez-Velez R . Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother. 2009; 64(6):1139-47. DOI: 10.1093/jac/dkp357. View

5.
Coura J, de Abreu L, Willcox H, PETANA W . [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation]. Rev Soc Bras Med Trop. 1997; 30(2):139-44. DOI: 10.1590/s0037-86821997000200009. View